Hikma Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	263	217	188	205	270	426
Trading Asset Securities	26	26	25	24	22	24
Cash & Short-Term Investments	289	243	213	229	292	450
Cash Growth	22.46%	14.09%	-6.99%	-21.57%	-35.11%	29.68%
Accounts Receivable	1,099	997	896	789	777	781
Other Receivables	22	82	77	84	64	95
Receivables	1,121	1,079	973	873	841	876
Inventory	1,176	1,106	986	891	776	695
Prepaid Expenses	95	87	73	72	74	65
Restricted Cash	-	111	-	-	-	-
Other Current Assets	62	17	18	35	16	8
Total Current Assets	2,743	2,643	2,263	2,100	1,999	2,094
Property, Plant & Equipment	1,511	1,448	1,326	1,141	1,081	1,146
Long-Term Investments	11	51	62	65	52	46
Goodwill	389	393	382	388	389	285
Other Intangible Assets	742	777	774	712	735	607
Long-Term Deferred Tax Assets	333	307	293	226	192	183
Other Long-Term Assets	100	52	33	48	23	11
Total Assets	5,830	5,671	5,133	4,680	4,471	4,372

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Accounts Payable	634	400	358	309	291	262
Accrued Expenses	-	480	439	388	272	305
Short-Term Debt	77	14	21	46	75	64
Current Portion of Long-Term Debt	117	92	621	104	64	48
Current Portion of Leases	10	8	11	11	9	9
Current Income Taxes Payable	103	74	78	74	73	57
Current Unearned Revenue	-	55	28	21	193	213
Other Current Liabilities	444	330	422	386	100	58
Total Current Liabilities	1,385	1,453	1,978	1,339	1,077	1,016
Long-Term Debt	1,676	1,445	607	975	1,074	651
Long-Term Leases	77	45	46	55	61	74
Long-Term Unearned Revenue	89	58	30	-	-	-
Long-Term Deferred Tax Liabilities	16	16	18	25	19	24
Other Long-Term Liabilities	49	48	133	77	92	140
Total Liabilities	3,292	3,065	2,812	2,471	2,323	1,905

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Common Stock	39	40	40	40	40	42
Additional Paid-In Capital	282	282	282	282	282	282
Retained Earnings	2,485	2,556	2,362	2,158	2,092	2,189
Comprehensive Income & Other	-283	-285	-374	-282	-279	-60
Total Common Equity	2,523	2,593	2,310	2,198	2,135	2,453
Minority Interest	15	13	11	11	13	14
Shareholders' Equity	2,538	2,606	2,321	2,209	2,148	2,467
Total Liabilities & Equity	5,830	5,671	5,133	4,680	4,471	4,372

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Total Debt	1,957	1,604	1,306	1,191	1,283	846
Net Cash (Debt)	-1,668	-1,361	-1,093	-962	-991	-396
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share	-7.55	-6.11	-4.89	-4.33	-4.41	-1.70
Filing Date Shares Outstanding	216.5	220.11	220.43	221.08	220.24	231.5
Total Common Shares Outstanding	216.5	220.11	220.43	221.08	220.24	231.5
Working Capital	1,358	1,190	285	761	922	1,078
Book Value Per Share	11.65	11.78	10.48	9.94	9.69	10.60
Tangible Book Value	1,392	1,423	1,154	1,098	1,011	1,561
Tangible Book Value Per Share	6.43	6.47	5.24	4.97	4.59	6.74
Land	-	933	851	797	725	676
Machinery	-	1,166	1,067	1,042	964	934
Construction In Progress	-	477	409	272	262	271